Management of vitiligo: a promising future

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Vitiligo is an autoimmune condition causing melanocyte destruction and depigmentation, affecting 0.5-1% globally.
• The condition significantly impacts patient quality of life due to visible and psychological burdens.
• Current vitiligo treatments often face challenges with relapse and inadequate patient response.

Purpose of the Study:

• To comprehensively review recent advancements in vitiligo treatment strategies.
• To evaluate the efficacy of established and emerging therapies, including topical, systemic, and physical modalities.
• To identify future research directions for improving vitiligo management outcomes.

Main Methods:

• A comprehensive literature review of dermatological and immunological studies was performed.
• Recent advancements in topical, systemic, and physical therapies for vitiligo were examined.
• Established treatments and novel agents like Janus kinase (JAK) inhibitors were analyzed.

Main Results:

• Topical agents (corticosteroids, calcineurin inhibitors) and ruxolitinib show efficacy in localized vitiligo.
• Oral JAK inhibitors are emerging as promising treatments for extensive vitiligo.
• Phototherapy (NB-UVB, excimer light) remains a gold standard, often combined with topical agents; surgical options exist for refractory cases.

Conclusions:

• Targeted therapies like JAK inhibitors offer new hope for vitiligo patients.
• Challenges persist in achieving sustained repigmentation and preventing disease relapse.
• Future research should optimize combination therapies and explore novel biologics for improved long-term vitiligo management.